Publications for Nick Lintzeris
|
|
- Britney Lawrence
- 5 years ago
- Views:
Transcription
1 Publications for Nick Lintzeris 2018 Lintzeris, N., Demirkol, A. (2018). A woman with pain and codeine withdrawal: Treatment to support opioid cessation. Medicine Today, 19(3 Suppl), Ridley, N., Batchelor, J., Draper, B., Demirkol, A., Lintzeris, N., Withall, A. (2018). Cognitive screening in substance users: Diagnostic accuracies of the Mini-Mental State Examination, Addenbrooke's Cognitive Examinationï ½Revised, and Montreal Cognitive Assessment. Journal of Clinical and Experimental Neuropsychology, 40(2), <a href=" e Lovell, M., Bruno, R., Johnston, J., Matthews, A., McGregor, I., Allsop, D., Lintzeris, N. (2018). Cognitive, physical, and mental health outcomes between long-term cannabis and tobacco users. Addictive Behaviors, 79, <a href=" Chronister, K., Lintzeris, N., Jackson, A., Ivan, M., Dietze, P., Lenton, S., Kearley, J., Van Beek, I. (2018). Findings and lessons learnt from implementing Australia's first health service based take-home naloxone program. Drug and Alcohol Review, 37, <a href=" Nielsen, S., Peacock, A., Lintzeris, N., Bruno, R., Larance, B., Degenhardt, L. (2018). Knowledge of Opioid Overdose and Attitudes to Supply of Take-Home Naloxone Among People with Chronic Noncancer Pain Prescribed Opioids. Pain Medicine, 19(3), <a href=" Bhardwaj, A., Allsop, D., Copeland, J., McGregor, I., Dunlop, A., Shanahan, M., Bruno, R., Phung, N., Montebello, M., Sadler, C., Gugusheff, J., Lintzeris, N., et al (2018). Randomised Controlled Trial (RCT) of cannabinoid replacement therapy (Nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocol. BMC Psychiatry, 18(1), 140. <a href=" Herzog, S., Shanahan, M., Grimison, P., Tran, A., Wong, N., Lintzeris, N., Simes, R., Stockler, M., Morton, R. (2018). Systematic Review of the Costs and Benefits of Prescribed Cannabis-Based Medicines for the Management of Chronic Illness: Lessons from Multiple Sclerosis. PharmacoEconomics, 36(1), <a href=" ">[More 2017 Suraev, A., Todd, L., Bowen, M., Allsop, D., McGregor, I., Ireland, C., Lintzeris, N. (2017). An Australian nationwide survey on medicinal cannabis use for epilepsy: History of antiepileptic drug treatment predicts medicinal cannabis use. Epilepsy and Behavior, 70, <a href=" Monds, L., Ridley, N., Rivas, C., Withall, A., Draper, B., Lintzeris, N. (2017). Cognition and adaptive functioning in older people attending drug and alcohol services. International Psychogeriatrics, 29(5), <a href=" Haber, P., Elsayed, M., Espinoza, D., Lintzeris, N., Veillard, A., Hallinan, R. (2017). Constipation and other common symptoms reported by women and men in methadone and buprenorphine maintenance treatment. Drug and Alcohol Dependence, 181, <a href=" re Nielsen, S., Gisev, N., Bruno, R., Hall, W., Cohen, M., Larance, B., Campbell, G., Shanahan, M., Blyth, F., Lintzeris, N., Pearson, S., et al (2017). Defined daily doses (DDD) do not accurately reflect opioid doses used in contemporary chronic pain treatment. Pharmacoepidemiology and Drug Safety, 26(5), <a href=" Dunlop, A., Brown, A., Oldmeadow, C., Harris, A., Gill, A., Sadler, C., Ribbons, K., Attia, J., Barker, D., et al, Lintzeris, N. (2017). Effectiveness and cost-effectiveness of unsupervised buprenorphine-naloxone for the treatment of heroin dependence in a randomized waitlist controlled trial. Drug and Alcohol Dependence, 174, <a href=" re Nielsen, S., Bruno, R., Degenhardt, L., Demirkol, A., Lintzeris, N. (2017). Opioid agonist doses for oxycodone and morphine dependence: Findings from a retrospective case series. Drug and Alcohol Review, 36(3), <a href=" Nielsen, S., Larance, B., Lintzeris, N. (2017). Opioid agonist treatment for patients with dependence on prescription opioids. JAMA - Journal of the American Medical Association, 317(9), <a href=" Nielsen, S., Sabioni, P., Trigo, J., Ware, M., Betz-Stablein, B., Murnion, B., Lintzeris, N., Khor, K., Farrell, M., Smith, A., et al (2017). Opioid-Sparing Effect of Cannabinoids: A Systematic Review and Meta-Analysis. Neuropsychopharmacology, 42(9), <a href=" Allsop, D., Rooney, K., Arnold, J., Bhardwaj, A., Brunu, R., Bartlett, D., Montebello, M., Arkell, T., Richards, E., Gugusheff, J., Rooke, S., Kerley, W., Murnion, B., Haber, P., McGregor, I., Lintzeris, N. (2017). Randomised controlled trial (RCT) of daily aerobic exercise for inpatient cannabis withdrawal: A study protocol. Mental Health and Physical Activity, 13, <a href=" Kevin, R., Allsop, D., Lintzeris, N., Dunlop, A., Booth, J., McGregor, I. (2017). Urinary cannabinoid levels during nabiximols (Sativex)-medicated inpatient cannabis withdrawal. Forensic Toxicology, 35(1), <a
2 href=" Deacon, R., Nielsen, E., Leung, S., Rivas, G., Cubitt, T., Monds, L., Ezard, N., Larance, B., Lintzeris, N. (2016). Alprazolam use and related harm among opioid substitution treatment clients - 12 months follow up after regulatory rescheduling. International Journal of Drug Policy, 36, <a href=" Luckett, T., Phillips, J., Lintzeris, N., Allsop, D., Lee, J., Solowij, N., Martin, J., Lam, L., Aggarwal, R., McCaffrey, N., Lovell, M., McGregor, I., et al (2016). Clinical trials of medicinal cannabis for appetite-related symptoms from advanced cancer: A survey of preferences, attitudes and beliefs among patients willing to consider participation. Internal Medicine Journal, 46(11), <a href=" Campbell, G., Bruno, R., Lintzeris, N., Cohen, M., Nielsen, S., Hall, W., Larance, B., Mattick, R., Blyth, F., Farrell, M., et al (2016). Defining problematic pharmaceutical opioid use among people prescribed opioids for chronic non-cancer pain: Do different measures identify the same patients? Pain, 157(7), <a href=" ore Larance, B., Bruno, R., Lintzeris, N., Degenhardt, L., Black, E., Brown, A., Nielsen, S., Dunlop, A., Holland, R., Cohen, M., et al (2016). Development of a brief tool for monitoring aberrant behaviours among patients receiving long-term opioid therapy: The Opioid-Related Behaviours In Treatment (ORBIT) scale. Drug and Alcohol Dependence, 159, <a href=" re Larance, B., Mattick, R., Ali, R., Lintzeris, N., Jenkinson, R., White, N., Kihas, I., Cassidy, R., Degenhardt, L. (2016). Diversion and injection of buprenorphine-naloxone film two years post-introduction in Australia. Drug and Alcohol Review, 35(1), <a href=" Arnold, J., Allsop, D., Lintzeris, N., McGregor, I. (2016). Evidence Check: Pharmacological actions and associated therapeutic levels of phytocannabinoids, (pp. 1-81). Sydney, Australia: The Sax Institute. Larance, B., Campbell, G., Peacock, A., Nielsen, S., Bruno, R., Hall, W., Lintzeris, N., Cohen, M., Degenhardt, L. (2016). Pain, alcohol use disorders and risky patterns of drinking among people with chronic non-cancer pain receiving long-term opioid therapy. Drug and Alcohol Dependence, 162, <a href=" re Kraus, M., Lintzeris, N., Maier, C., Savage, S. (2016). Recommendations for the Prevention, Detection, Treatment and Management of Prescription Opioid Analgesic Dependence: Outcomes From the Opioid Analgesic Dependence Education Nexus (OPEN) Meeting. International Journal of Mental Health and Addiction, 14(3), <a href=" Peacock, A., Bruno, R., Larance, B., Lintzeris, N., Nielsen, S., Ali, R., Dobbins, T., Degenhardt, L. (2016). Same-day use of opioids and other central nervous system depressants amongst people who tamper with pharmaceutical opioids: A retrospective 7-day diary study. Drug and Alcohol Dependence, 166, <a href=" re Lintzeris, N., Moodley, R., Campbell, G., Larance, B., Bruno, R., Nielsen, E., Degenhardt, L. (2016). Sleep quality among people living with chronic noncancer pain: Findings from the pain and opioids in treatment (POINT) cohort. Clinical Journal of Pain, 32(5), <a href=" e Ezard, N., Dunlop, A., Clifford, B., Bruno, R., Carr, A., Bissaker, A., Lintzeris, N. (2016). Study protocol: A doseescalating, phase-2 study of oral lisdexamfetamine in adults with methamphetamine dependence. BMC Psychiatry, 16(1), 1-8. <a href=" x">[more Lintzeris, N., Rivas, C., Monds, L., Leung, S., Withall, A., Draper, B. (2016). Substance use, health status and service utilisation of older clients attending specialist drug and alcohol services. Drug and Alcohol Review, 35(2), <a href=" Lintzeris, N., Monds, L., Rivas, G., Leung, S., Withall, A., Draper, B. (2016). The Australian Treatment Outcomes Profile instrument as a clinical tool for older alcohol and other drug clients: A validation study. Drug and Alcohol Review, 35(6), <a href=" Nielsen, S., Bruno, R., Murnion, B., Dunlop, A., Degenhardt, L., Demirkol, A., Muhleisen, P., Lintzeris, N. (2016). Treating codeine dependence with buprenorphine: Dose requirements and induction outcomes from a retrospective case series in New South Wales, Australia. Drug and Alcohol Review, 35(1), <a href=" Peacock, A., Degenhardt, L., Larance, B., Cama, E., Lintzeris, N., Ali, R., Bruno, R. (2015). A typology of people who tamper with pharmaceutical opioids: responses to introduction of a tamper-resistant formulation of controlled-release oxycodone. Pharmacoepidemiology and Drug Safety, 24(12), <a href=" Degenhardt, L., Bruno, R., Lintzeris, N., Hall, W., Nielsen, S., Larance, B., Cohen, M., Campbell, G. (2015). Agreement between definitions of pharmaceutical opioid use disorders and dependence in people taking opioids for chronic non-cancer pain (POINT): A cohort study. The Lancet Psychiatry, 2(4), <a href=" Nielsen, S., Lintzeris, N., Bruno, R., Campbell, G., Larance, B., Hall, W., Hoban, B., Cohen, M., Degenhardt, L. (2015). Benzodiazepine Use among Chronic Pain Patients Prescribed Opioids: Associations with Pain, Physical and Mental Health, and Health Service Utilization. Pain Medicine, 16(2), <a href=" Allsop, D., Lintzeris, N., Copeland, J., Dunlop, A., McGregor, I. (2015). Cannabinoid Replacement Therapy (CRT): Nabiximols (Sativex) as a Novel Treatment for Cannabis Withdrawal. Clinical Pharmacology & Therapeutics, 97(6), <a href="
3 Nielsen, S., Roxburgh, A., Bruno, R., Lintzeris, N., Jefferson, A., Degenhardt, L. (2015). Changes in non-opioid substitution treatment episodes for pharmaceutical opioids and heroin from 2002 to Drug and Alcohol Dependence, 149, <a href=" re Nielsen, S., Murnion, B., Dunlop, A., Degenhardt, L., Demirkol, A., Muhleisen, P., Lintzeris, N. (2015). Comparing treatment-seeking codeine users and strong opioid users: Findings from a novel case series. Drug and Alcohol Review, 34(3), <a href=" Metrebian, N., Groshkova, T., Hellier, J., Charles, V., Martin, A., Forzisi, L., Lintzeris, N., Zador, D., Williams, H., Carnwath, T., et al (2015). Drug use, health and social outcomes of hard-to-treat heroin addicts receiving supervised injectable opiate treatment: Secondary outcomes from the Randomized Injectable Opioid Treatment Trial (RIOTT). Addiction, 110(3), <a href=" Degenhardt, L., Larance, B., Bruno, R., Lintzeris, N., Ali, R., Farrell, M. (2015). Evaluating the potential impact of a reformulated version of oxycodone upon tampering, nonadherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol. Addiction, 110(2), <a href=" Degenhardt, L., Lintzeris, N., Campbell, G., Bruno, R., Cohen, M., Farrell, M., Hall, W. (2015). Experience of adjunctive cannabis use for chronic non-cancer pain: Findings from the Pain and Opioids IN Treatment (POINT) study. Drug and Alcohol Dependence, 147, <a href=" re Strang, J., Groshkova, T., Uchtenhagen, A., van den Brink, W., Haasen, C., Schechter, M., Lintzeris, N., Bell, J., Pirona, A., Oviedo-Joekes, E., et al (2015). Heroin on trial: Systematic review and meta-analysis of randomised trials of diamorphineprescribing as treatment for refractory heroin addiction. British Journal of Psychiatry, 207(1), <a href=" White, N., Flaherty, I., Higgs, P., Larance, B., Nielsen, S., Degenhardt, L., Ali, R., Lintzeris, N. (2015). Injecting buprenorphine-naloxone film: Findings from an explorative qualitative study. Drug and Alcohol Review, 34(6), <a href=" Peacock, A., Bruno, R., Cama, E., Kihas, I., Larance, B., Lintzeris, N., Hordern, A., White, N., Ali, R., Degenhardt, L. (2015). Jurisdictional differences in opioid use, other licit and illicit drug use, and harms associated with substance use among people who tamper with pharmaceutical opioids. Drug and Alcohol Review, 34(6), <a href=" Lintzeris, N. (2015). Opiods. In Paul Haber, Carolyn Day, Michael Farrell (Eds.), Addiction Medicine: Principles and Practice, (pp ). Melbourne: IP Communications. Campbell, G., Nielsen, S., Larance, B., Bruno, R., Mattick, R., Hall, W., Lintzeris, N., Cohen, M., Smith, K., Degenhardt, L. (2015). Pharmaceutical Opioid Use and Dependence among People Living with Chronic Pain: Associations Observed within the Pain and Opioids in Treatment (POINT) Cohort. Pain Medicine, 16(9), <a href=" Wang, D., Lintzeris, N., Leung, S., Haber, P., Yee, B., Grunstein, R. (2015). Reversal of central sleep apnoea with change from methadone to buprenorphine-naloxone: a case report. European Respiratory Journal, 46(4), <a href=" Draper, B., Ridley, N., Johnco, C., Withall, A., Welkee, S., Freeman, M., Contini, E., Lintzeris, N. (2015). Screening for alcohol and substance use for older people in geriatric hospital and community health settings. International Psychogeriatrics, 27(1), <a href=" Larance, B., Lintzeris, N., Bruno, R., Peacock, A., Cama, E., Ali, R., Kihas, I., Hordern, A., White, N., Degenhardt, L. (2015). The characteristics of a cohort who tamper with prescribed and diverted opioid medications. Journal of Substance Abuse Treatment, 58, <a href=" Allsop, D., Bartlett, D., Johnston, J., Helliwell, D., Winstock, A., McGregor, I., Lintzeris, N. (2015). The Effects of Lithium Carbonate Supplemented with Nitrazepam on Sleep Disturbance during Cannabis Abstinence. The Journal of Clinical Sleep Medicine, 11(10), <a href=" Degenhardt, L., Bruno, R., Ali, R., Lintzeris, N., Farrell, M., Larance, B. (2015). The introduction of a potentially abuse deterrent oxycodone formulation: Early findings from the Australian National Opioid Medications Abuse Deterrence (NOMAD) study. Drug and Alcohol Dependence, 151, <a href=" re Larance, B., Dietze, P., Ali, R., Lintzeris, N., White, N., Jenkinson, R., Degenhardt, L. (2015). The introduction of buprenorphine-naloxone film in opioid substitution therapy in Australia: Uptake and issues arising from changing buprenorphine formulations. Drug and Alcohol Review, 34(6), <a href=" Campbell, G., Nielsen, S., Bruno, R., Lintzeris, N., Cohen, M., Hall, W., Larance, B., Mattick, R., Degenhardt, L. (2015). The Pain and Opioids IN Treatment study: characteristics of a cohort using opioids to manage chronic non-cancer pain. Pain, 156(2), <a href=" >[More Hoban, B., Larance, B., Gisev, N., Nielsen, S., Cohen, M., Bruno, R., Shand, F., Lintzeris, N., Hall, W., Farrell, M., et al (2015). The use of paracetamol (acetaminophen) among a community sample of people with chronic non-cancer pain prescribed opioids. International Journal of Clinical Practice, 69(11), <a href=" Lintzeris, N. (2015). Treatment of patients with opioid dependence. Medicine Today, 16(6),
4 Larance, B., Carragher, N., Mattick, R., Lintzeris, N., Ali, R., Degenhardt, L. (2014). A latent class analysis of self-reported clinical indicators of psychosocial stability and adherence among opioid substitution therapy patients: Do stable patients receive more unsupervised doses? Drug and Alcohol Dependence, 142, <a href=" re Lofwall, M., Martin, J., Tierney, M., Fatseas, M., Auriacombe, M., Lintzeris, N. (2014). Buprenorphine diversion and misuse in outpatient practice. Journal of Addiction Medicine, 8(5), <a href=" ore Campbell, G., Mattick, R., Bruno, R., Larance, B., Nielsen, S., Cohen, M., Lintzeris, N., Shand, F., Hall, W., Hoban, B., et al (2014). Cohort protocol paper: the Pain and Opioids In Treatment (POINT) study. BMC Pharmacology & Toxicology, 15(1), 1-9. <a href=" Belcher, J., Nielsen, S., Campbell, G., Bruno, R., Hoban, B., Larance, B., Lintzeris, N., Degenhardt, L. (2014). Diversion of prescribed opioids by people living with chronic pain: Results from an Australian community sample. Drug and Alcohol Review, 33(1), <a href=" Johnston, J., Lintzeris, N., Allsop, D., Suraev, A., Booth, J., Carson, D., Helliwell, D., Winstock, A., McGregor, I. (2014). Lithium carbonate in the management of cannabis withdrawal: a randomized placebo-controlled trial in an inpatient setting. Psychopharmacology, 231(24), <a href=" Allsop, D., Copeland, J., Lintzeris, N., Dunlop, A., Montebello, M., Sadler, C., Rivas, G., Holland, R., Muhleisen, P., Norberg, M., Booth, J., McGregor, I. (2014). Nabiximols as an Agonist Replacement Therapy During Cannabis Withdrawal: A Randomized Clinical Trial. JAMA Psychiatry, 71(3), <a href=" ore Larance, B., Lintzeris, N., Ali, R., Dietze, P., Mattick, R., Jenkinson, R., White, N., Degenhardt, L. (2014). The diversion and injection of a buprenorphine-naloxone soluble film formulation. Drug and Alcohol Dependence, 136(1), <a href=" re 2013 Lintzeris, N., Leung, S., Dunlop, A., Larance, B., White, N., Rivas, G., Holland, R., Degenhardt, L., Muhleisen, P., Hurley, M., et al (2013). A randomised controlled trial of sublingual buprenorphine-naloxone film versus tablets in the management of opioid dependence. Drug and Alcohol Dependence, 131(1-2), <a href=" re Holliday, S., Magin, P., Dunbabin, J., Oldmeadow, C., Henry, J., Lintzeris, N., Attia, J., Goode, S., Dunlop, A. (2013). An Evaluation of the Prescription of Opioids for Chronic Nonmalignant Pain by Australian General Practitioners. Pain Medicine, 14(1), <a href=" Holliday, S., Magin, P., Oldmeadow, C., Attia, J., Dunbabin, J., Henry, J., Lintzeris, N., Goode, S., Dunlop, A. (2013). An examination of the influences on New South Wales general practitioners regarding the provision of opioid substitution therapy. Drug and Alcohol Review, 32(5), <a href=" Nielsen, S., Larance, B., Lintzeris, N., Black, E., Bruno, R., Murnion, B., Dunlop, A., Degenhardt, L. (2013). Correlates of pain in an in-treatment sample of opioid-dependent people. Drug and Alcohol Review, 32(5), <a href=" Wong, A., Montebello, M., Norberg, M., Rooney, K., Lintzeris, N., Bruno, R., Booth, J., Arnold, J., McGregor, I. (2013). Exercise increases plasma THC concentrations in regular cannabis users. Drug and Alcohol Dependence, 133(2), <a href=" re Nielsen, S., Bruno, R., Degenhardt, L., Stoove, M., Fischer, J., Carruthers, S., Lintzeris, N. (2013). The sources of pharmaceuticals for problematic users of benzodiazepines and prescription opioids. Medical Journal of Australia, 199(10), <a href=" Groshkova, T., Metrebian, N., Hallam, C., Charles, V., Martin, A., Forzisi, L., Lintzeris, N., Strang, J. (2013). Treatment expectations and satisfaction of treatment-refractory opioiddependent patients in RIOTT, the Randomised Injectable Opiate Treatment Trial, the UK's first supervised injectable maintenance clinics. Drug and Alcohol Review, 32(6), <a href=" Day, C., Demirkol, A., Tynan, M., Curry, K., Hines, S., Lintzeris, N., Haber, P. (2012). Individual versus team-based case-management for clients of opioid treatment services: An initial evaluation of what clients prefer. Drug and Alcohol Review, 31(4), <a x">[More Black, K., Haber, P., Lintzeris, N. (2012). Offering incentives to drug-using women to take up contraception: The ethical and clinical issues. Addiction, 107(7), <a href=" Black, K., Stephens, C., Haber, P., Lintzeris, N. (2012). Unplanned pregnancy and contraceptive use in women attending drug treatment services. Australian and New Zealand Journal of Obstetrics and Gynaecology, 52(2), <a href=" Winstock, A., Lintzeris, N., Lea, T. (2011). 'Should I stay or should I go?' Coming off methadone and buprenorphine treatment. International Journal of Drug Policy, 22(1), <a href=" Larance, B., Degenhardt, L., Lintzeris, N., Winstock, A., Mattick, R. (2011). Definitions related to the use of pharmaceutical opioids: Extramedical use, diversion, non-
5 adherence and aberrant medication-related behaviours. Drug and Alcohol Review, 30(3), <a x">[More Longman, C., Lintzeris, N., Temple-Smith, M., Gilchrist, G. (2011). Methadone and buprenorphine prescribing patterns of Victorian general practitioners: Their first 5 years after authorisation. Drug and Alcohol Review, 30(4), <a x">[More Mayet, S., Gossop, M., Lintzeris, N., Markides, V., Strang, J. (2011). Methadone maintenance, QTc and torsade de pointes: Who needs an electrocardiogram and what is the prevalence of QTc prolongation? Drug and Alcohol Review, 30(4), <a x">[More Nielsen, S., Bruno, R., Lintzeris, N., Fischer, J., Carruthers, S., StoovÃ, M. (2011). Pharmaceutical opioid analgesic and heroin dependence: How do treatment-seeking clients differ in Australia? Drug and Alcohol Review, 30(3), <a x">[More Larance, B., Degenhardt, L., Lintzeris, N., Bell, J., Winstock, A., Dietze, P., Mattick, R., Ali, R., Horyniak, D. (2011). Postmarketing surveillance of buprenorphine-naloxone in Australia: Diversion, injection and adherence with supervised dosing. Drug and Alcohol Dependence, 118(2011), <a href=" re Douglas, H., Boyle, M., Lintzeris, N. (2011). The health impacts of khat: a qualitative study among Somali-Australians. Medical Journal of Australia, 195(11), <a href=" Lintzeris, N., Nielsen, S. (2010). Benzodiazepines, methadone and buprenorphine: interactions and clinical management. American Journal on Addictions, 19(1), <a href=" Lintzeris, N. (2010). Commentary on Blanken et al. (2010): long-term heroin-assisted treatment-some more questions and answers. Addiction, 105(2), <a href=" Sanson-Fisher, R., Brand, M., Shakeshaft, A., Haber, P., Day, C., Conigrave, K., Mattick, R., Lintzeris, N., Teesson, M. (2010). Forming a national multicentre collaboration to conduct clinical trials: increasing high-quality research in the drug and alcohol field. Drug and Alcohol Review, 29(5), <a x">[More Forzisi, L., Mitchell, T., Bond, A., Lintzeris, N., Spofforth, N., Strang, J. (2010). Psychological Performance and Sedation Following Injectable Opioid Administration. Heroin Addiction and Related Clinical Problems, 12(3), 5-8. Miller, P., McKenzie, S., Lintzeris, N., Martin, A., Strang, J. (2010). The Community Impact of RIOTT, a Medically Supervised Injectable Maintenance Clinic in South London. Mental Health and Substance Use, 3(3), <a href=" Ramasamy, P., Lintzeris, N., Sutton, Y., Taylor, H., Day, C., Haber, P. (2010). The outcome of a rapid hepatitis B vaccination programme in a methadone treatment clinic. Addiction, 105(2), <a href=" Ridge, G., Gossop, M., Lintzeris, N., Witton, J., Strang, J. (2009). Factors associated with the prescribing of buprenorphine or methadone for treatment of opiate dependence. Journal of Substance Abuse Treatment, 37(1), <a href=" Bammer, G., Ritter, A., Kutin, J., Lintzeris, N. (2009). Fasttracking implementation through trial design: the case of buprenorphine treatment in Victoria. Australian and New Zealand Journal of Public Health, 33(1), <a href=" Miller, P., Forzisi, L., Zador, D., Lintzeris, N., Metrebian, N., Waal, R., Mayet, S., Strang, J. (2009). Groin injecting in injectable opioid treatment service users in South London. Addiction Research and Theory, 17(4), <a href=" Haber, P., Lintzeris, N., Proude, E., Lopatko,, O. (2009). Guidelines for the Treatment of Alcohol Problems, Publications Number: P3-5625, (pp. vii - 232). Canberra, Australia: Commonwealth Department of Health and Ageing. Degenhardt, L., Larance, B., Bell, J., Winstock, A., Lintzeris, N., Ali, R., Scheuer, N. (2009). Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist-antagonist formulation. Medical Journal of Australia, 191(3), <a href=" eve&db=pubmed&dopt=abstract&list_uids= ">[more Haber, P., Lintzeris, N., Morley, K. (2009). Pharmacotherapies for alcohol dependence. In Paul Haber, Elizabeth Proude, Nick Lintzeris & Olga Lopatko (Eds.), Guidelines for the Treatment of Alcohol Problems, (pp ). Australia: Commonwealth of Australia. Lintzeris, N. (2009). Prescription of heroin for the management of heroin dependence: Current status. CNS Drugs, 23(6), <a href=" ">[More Winstock, A., Lintzeris, N., Lea, T. (2009). Why do patients report transferring between methadone and buprenorphine? Drug and Alcohol Review, 28(6), <a x">[More 2008 Lintzeris, N., van der Waal, R., Miller, P., Metrebian, N., Strang, J., Zador, D. (2008). The fine line between harm reduction and harm production - development of a clinical policy on femoral (groin) Injecting. European Addiction Research, 14(4), <a href=" Lintzeris, N., Lee, S., Scopelliti, L., Mabbutt, J., Haber, P. (2008). Unplanned admissions to two Sydney public hospitals after naltrexone implants. Medical Journal of Australia, 188(8), <a href="
6 eve&db=pubmed&dopt=abstract&list_uids= ">[more 2005 Digiusto, E., Lintzeris, N., Breen, C., Kimber, J., Mattick, R., Bell, J., Ali, R., Saunders, J. (2005). Short-term outcomes of five heroin detoxification methods in the Australian NEPOD Project. Addictive Behaviors, 30(3), <a href="
Etat des lieux des traitements méthadone et buprénorphine. A/Prof Adrian Dunlop Biarritz 2015
Etat des lieux des traitements méthadone et buprénorphine A/Prof Adrian Dunlop Biarritz 2015 Summary Methadone and buprenorphine in Australia Comparing treatments Effectiveness Australian studies Mortality
More informationClinical Guidelines and Procedures for the Use of Naltrexone in the Management of Opioid Dependence Abbreviated Version
Clinical Guidelines and Procedures for the Use of Naltrexone in the Management of Opioid Dependence Abbreviated Version Clinical Guidelines and Procedures for the Use of Naltrexone in the Management of
More informationPrescription drug abuse A timely update
FOCUS Prescription drug abuse A timely update Benny Monheit, Danusia Pietrzak, Sandra Hocking Background Prescription drug abuse is a rising problem in Australia and pharmaceutical drugs have been the
More informationCESPHN Webinar. Using opioid agonist treatment for pharmaceutical opioid dependence
CESPHN Webinar Using opioid agonist treatment for pharmaceutical opioid dependence Acknowledgements This webinar was produced for Central and Eastern Sydney Primary Health Network 2 Learning objectives
More informationOUTCOMES OF TRAINING GENERAL PRACTITIONERS TO PRESCRIBE METHADONE
LIBBY HOTHAM, ANN M ROCHE, EMMA FITZGERALD OUTCOMES OF TRAINING GENERAL PRACTITIONERS TO PRESCRIBE METHADONE LIBBY HOTHAM, ANN M ROCHE, EMMA FITZGERALD Over the last decade, most jurisdictions throughout
More informationSouth london and maudsley NHS Foundation Trust, (United Kingdom) patient care, management, research, teaching. Director, The Langton Centre
Curriculum Vitae PERSONAL INFORMATION James Bell WORK EXPERIENCE April 2009 Present Consultant Physician South london and maudsley NHS Foundation Trust, (United Kingdom) patient care, management, research,
More informationThe 2017 Orange Guidelines consideration of supervised heroin prescribing
The 2017 Orange Guidelines consideration of supervised heroin prescribing Dr Brian Kidd MD University of Dundee Chair OG5 medical treatments sub-group 2014-17 Declarations I have received no other payments
More informationBuprenorphine pharmacology
Buprenorphine pharmacology Victorian Opioid Management ECHO Department of Addiction Medicine St Vincent s Hospital Melbourne 2018 Page 1 Opioids full, partial, antagonist Full Agonists - bind completely
More informationOverview of nonmedical. pharmaceutical opioids in Australia. Marissa Veld March 2018, QT Hotel Canberra
Overview of nonmedical use of pharmaceutical opioids in Australia Marissa Veld 27-28 March 2018, QT Hotel Canberra Introduction What are pharmaceutical opioids? Defining non-medical use Common pharmaceutical
More informationA Snapshot of Substance Use: Licit and Illicit Drug Use Yesterday among People Who Inject Drugs in Australia ( ).
illicit drug reporting system july 2016 A Snapshot of Substance Use: Licit and Illicit Drug Use Yesterday among People Who Inject Drugs in Australia (2006-2015). Authors: Amy Peacock 1,2, Bethany Lusk
More informationModels of good practice in drug treatment in Europe. Project group
Models of good practice in drug treatment in Europe ( moretreat 2006329 ) Project group Hamburg, London, Rome, Stockholm, Vienna, Warsaw, Zurich Project duration: 17 months from April 2006 August 2008
More informationThe available evidence in the field of treatment of opiate: The experience of developing the WHO clinical guidelines
The available evidence in the field of treatment of opiate: The experience of developing the WHO clinical guidelines Background, Objectives and Methods Systematic reviews (SRs) published by Cochrane Drugs
More informationAnalgesia for Patients with Substance Abuse Disorders. Lisa Jennings CN November 2015
Analgesia for Patients with Substance Abuse Disorders Lisa Jennings CN November 2015 Definitions n Addiction: A pattern of drug use characterised by aberrant drug-taking behaviours & the compulsive use
More informationNational Opioid Treatment Guideline Dr. Ronald Lim
National Opioid Treatment Guideline Dr. Ronald Lim (MD, CCFP, DFASAM, ABAM(D), FISAM, CCSAM, MRO) Clinical Assistant Professor, Department of Psychiatry and Family Practice Cumming School of Medicine University
More informationClinical Policy Bulletin: Naltrexone Implants
Naltrexone Implants Page 1 of 5 Clinical Policy Bulletin: Naltrexone Implants Number: 0878 Policy Aetna considers naltrexone implants experimental and investigational for treatment of alcohol addiction,
More informationEffect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study
Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study Gabrielle Campbell, Wayne D Hall, Amy Peacock, Nicholas Lintzeris, Raimondo
More informationPERSPECTIVES ON DRUGS Strategies to prevent diversion of opioid substitution treatment medications
UPDATED 31. 5. 2016 PERSPECTIVES ON DRUGS Strategies to prevent diversion of opioid substitution treatment medications The use of substitution drugs for the treatment of opioid dependence represents a
More informationSUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets. Risk Evaluation and Mitigation Strategy (REMS) Program
SUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets Risk Evaluation and Mitigation Strategy (REMS) Program Office-Based Buprenorphine Therapy for Opioid Dependence: Important Information for Prescribers
More informationBuprenorphine for Family Medicine. Hannah Snyder, MD Addiction Medicine Fellow, UCSF 12/7/17
+ Buprenorphine for Family Medicine Hannah Snyder, MD Addiction Medicine Fellow, UCSF 12/7/17 + Disclosures No conflicts of interest Off-label use of medications + Who here: Has taken care of a patient
More informationDrug related hospital stays in Australia
Prepared by Funded by Amanda Roxburgh and Courtney Breen, National Drug and Alcohol Research Centre the Australian Government Department of Health Recommended Roxburgh, A. and Breen, C (217). Drug-related
More informationOpioids Research to Practice
Opioids Research to Practice CRIT Program May 2009 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin
More informationBuprenorphine: An Introduction. Sharon Stancliff, MD Harm Reduction Coalition September 2008
Buprenorphine: An Introduction Sharon Stancliff, MD Harm Reduction Coalition September 2008 Objective Participants will be able to: Discuss the role of opioid maintenance in reducing morbidity and mortality
More informationKurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center
Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center Data from the National Vital Statistics System Mortality The age-adjusted rate of drug overdose deaths in the United States
More informationOpiate Dependency bka Opioid Addiction
Opiate Dependency bka Opioid Addiction GP CME Dunedin July 2012 Doug Sellman Professor of Psychiatry and Addiction Medicine Director, National Addiction Centre University of Otago, Christchurch What this
More informationPublic Health Association of Australia: Policy-at-a-glance Pharmaceutical Drug Misuse Policy
Public Health Association of Australia: Policy-at-a-glance Pharmaceutical Drug Misuse Policy Key message: Summary: Audience: Responsibility: 1. Pharmaceutical drugs, when used as intended as part of quality
More informationHA Corporate Scholarship Program:
HA Corporate Scholarship Program: Substance Abuse Service in Psychiatry Ronnie Pao 02-10-10 The Maudsley Hospital Marina House Community Drug & Alcohol Team London Borough of Southwark Provides a Tier
More informationMedication-Assisted Treatment. What Is It and Why Do We Use It?
Medication-Assisted Treatment What Is It and Why Do We Use It? What is addiction, really? o The four C s of addiction: Craving. Loss of Control of amount or frequency of use. Compulsion to use. Use despite
More informationPopulation planning for alcohol and other drug services: the national Drug and Alcohol Clinical Care & Prevention (DA-CCP) project
Population planning for alcohol and other drug services: the national Drug and Alcohol Clinical Care & Prevention (DA-CCP) project History and context Service planning poorly done How many services do
More informationBuprenorphine as a Treatment Option for Opioid Use Disorder
Buprenorphine as a Treatment Option for Opioid Use Disorder Joji Suzuki, MD Assistant Professor of Psychiatry Harvard Medical School Director, Division of Addiction Psychiatry Brigham and Women s Hospital
More informationAn overview of Medication Assisted Treatment (MAT) and acute pain management on MAT
An overview of Medication Assisted Treatment (MAT) and acute pain management on MAT Goals of Discussion Recognize opioid use disorder (OUD) Discuss the pharmacology of medication assisted treatments (MAT)
More informationMedication-Assisted Treatment (MAT) Overview
Medication-Assisted Treatment (MAT) Overview 2014 Opiate Conference: Don t Get Me Started Hyatt Regency, Columbus, Ohio June 30-July 1, 2014 Christina M. Delos Reyes, MD Medical Consultant, Center for
More informationTake-home naloxone to prevent heroin/opioid overdose deaths: a UK/Australia shared vision
Take-home naloxone to prevent heroin/opioid overdose deaths: a UK/Australia shared vision Professor Sir John Strang National Addiction Centre, King s College London, UK Declarations (personal & institutional)
More informationRESEARCH INTRODUCTION. Addiction Centre, Institute of Psychiatry, London SE5 8BB, UK 2 School of Population Health,
1 King s College London, National Addiction Centre, Institute of Psychiatry, London SE5 8BB, UK 2 School of Population Health, University of Queensland, Australia 3 Social Medicine, University of Bristol,
More informationOpioid Step Policy. Description. Section: Prescription Drugs Effective Date: April 1, 2018
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Opioid Step Policy Page: 1 of 6 Last Review Date: March 16, 2018 Opioid Step Policy Description
More informationOpioids Research to Practice
Opioids Research to Practice CRIT Program May 2008 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin
More informationClinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)
Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT) For Apple Health clients served Fee-for-Service and through contracted Medicaid Managed Care Organizations Updated January
More informationReferral to the Women s Alcohol and Drug Service (WADS) Procedure
Procedure Referral to the Women s Alcohol and Drug Service (WADS) Procedure. Purpose The following document describes criteria for the referral to Women s Alcohol and Drug Service (WADS) and how a referral
More informationClinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)
Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT) What has changed? Effective January 16, 2018, Coordinated Care will change the requirement for form HCA 13-333 Medication
More informationLONG TERM PHARMACOTHERAPY OF OPIOID DEPENDENCE
LONG TERM PHARMACOTHERAPY OF OPIOID DEPENDENCE DR. SHILPA ADARKAR ASSOCIATE PROFESSOR DEPARTMENT OF PSYCHIATRY & DRUG DEADDICTION CENTRE OF EXCELLENCE SETH GSMC & KEMH LONG TERM OPTIONS FULL AGONIST PARTIAL
More informationOpioids Research to Practice
Opioids Research to Practice CRIT Program May 2010 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin
More informationBuilding capacity for a CHC response to Ontario's Opioid Crisis
Building capacity for a CHC response to Ontario's Opioid Crisis Rob Boyd Oasis Program Director Luc Cormier, RN, MScN Community Health Nurse Sandy Hill Community Health Centre #AOHC2016 @rboyd6 @SandyHillCHC
More informationOpioid Use in Youth. Amy Yule M.D. March 2,
Opioid Use in Youth Amy Yule M.D. March 2, 2018 An opioid is a substance that acts on opioid receptors Beta-endorphin Endogenous opioids Dynorphin Opiates Natural products of the poppy plant Morphine Heroin
More informationOptimizing Opioid Dependence Treatment A Guideline for Pharmacists
Optimizing Opioid Dependence Treatment A Guideline for Pharmacists Module 3: Optimal Use of Methadone F e b r u a r y 2 0 1 5 Learning Objectives To know and understand the pathophysiology of substance
More informationYouth, Opioid Use and Treatment Options. CPSO MMT Providers Conference Dr. Sharon Cirone MD FCFPC November 2016
Youth, Opioid Use and Treatment Options CPSO MMT Providers Conference Dr. Sharon Cirone MD FCFPC November 2016 Disclosures No propriety involvement in pharmaceutical companies Assessor, CPSO Methadone
More informationClinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction
Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction Multiple Choice Identify the choice that best completes the statement or answers the question. 1. Executive Summary
More informationUnderstanding and Combating the Heroin Epidemic
Understanding and Combating the Heroin Epidemic Kelly Dunn, Ph.D. Assistant Professor; Johns Hopkins School of Medicine Department of Psychiatry and Behavioral Sciences 1 Talk Outline What is causing the
More informationPolicy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04
Policy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04 Date issued Issue 1 Nov 2018 Planned review Nov 2021 PPT-PGN 18 part of NTW(C)38 Pharmaceutical
More informationTreating Opioid Use Disorders: An Update for Counselors and Other Providers
Treating Opioid Use Disorders: An Update for Counselors and Other Providers Brad Shapiro, MD Medical Director Opiate Treatment Outpatient Program Zuckerberg San Francisco General THE DOSING WINDOW HISTORICAL
More informationWhat is harm reduction?
What is harm reduction? The International Harm Reduction Association (IHRA) defines harm reduction as the policies, programmes and practices that aim to reduce the harms associated with the use of psychoactive
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Drug Misuse: opiate detoxification of drug misusers in the community, hospital and prison. 1.1 Short title Drug misuse detoxification
More informationBASIC VOLUME. Elements of Drug Dependence Treatment
BASIC VOLUME Elements of Drug Dependence Treatment Module 3 Principles of CBT and relapse prevention strategies Introduction to Cognitive Behavioural Therapy Basics of pharmacological treatment Workshop
More informationCannabis and cannabinoids for medicinal purposes
Cannabis and cannabinoids for medicinal purposes International Evidence and Evidence for Practice in Australia Michael Farrell Louisa Degenhardt, Wayne Hall, Nicholas Buckley, Megan Weir, Suzi Neilsen,
More informationPERSPECTIVES ON DRUGS Preventing overdose deaths in Europe
UPDATED 15. 5. 2015 PERSPECTIVES ON DRUGS Preventing overdose deaths in Europe It is estimated that over 70 000 lives were lost to drug overdoses in Europe in the first decade of the 21st Century. Reducing
More informationCOSMPOLITAN COCKTAILS
References for Anex Bulletin Volume 8, Edition 2, November 2009. COSMPOLITAN COCKTAILS * Not her real name. 1 Tönne, U, Hiltunen, A. J, Engelbrektsson, K, Björvell, H, Vikander, B, Borg, S (1998): Personality
More informationNorth American Opiate Medication Initiative (NAOMI)
North American Opiate Medication Initiative (NAOMI) Multi-Centre, Randomized Controlled Trial of Heroin-Assisted Therapy for Treatment- Refractory Injection Opioid Users File Number: 9427-U0146-75C CTA
More informationSHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE
SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE INDICATION Naltrexone is a pure opiate antagonist licensed as an adjunctive prophylactic therapy in the maintenance
More informationNoel Schenk MD. Davis Behavioral Health
Noel Schenk MD Davis Behavioral Health Michael Botticelli Director of National Drug Control Policy What is Addiction? Addiction is defined as a chronic, relapsing brain disease that is characterized by
More informationMedical Assisted Treatment. Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center
Medical Assisted Treatment Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center Current Trends Prescription Drug Abuse/Addiction Non-medical use of prescription pain killers
More informationRates of Opioid Overdose Deaths, Sales, and Treatment Admissions: US,
Rates of Opioid Overdose Deaths, Sales, and Treatment Admissions: US, 1999 21 8 Rates of Prescription Painkiller Sales, Deaths, and Substance Abuse Treatment Admissions (1999 21) 7 Rate 6 5 4 3 Sales per
More informationClinical Toxicology: An Update
Clinical Toxicology: An Update Dr. Shaun Greene VICTORIAN POISONS INFORMATION CENTRE AND AUSTIN HOSPITAL CLINICAL TOXICOLOGY SERVICE Drug Abuse in Australasia VICTORIAN POISONS INFORMATION CENTRE AND AUSTIN
More informationOpiate Use Disorder and Opiate Overdose
Opiate Use Disorder and Opiate Overdose Irene Ortiz, MD Medical Director Molina Healthcare of New Mexico and South Carolina Clinical Professor University of New Mexico School of Medicine Objectives DSM-5
More informationPrepublication Requirements
Issued Prepublication Requirements The Joint Commission has approved the following revisions for prepublication. While revised requirements are published in the semiannual updates to the print manuals
More informationThe CARA & Buprenorphine Prescribing for APNs & PAs
The CARA & Buprenorphine Prescribing for APNs & PAs William J. Lorman, JD, PhD, MSN, PMHNP-BC, CARN-AP FIAAN Assistant Clinical Professor, Drexel University, Philadelphia, PA V. P. & Chief Clinical Officer,
More informationNeonatal Abstinence Syndrome Questions & Answers Webinar #1 (February 9, 2012) Webinar #2 (March 30, 3012)
Neonatal bstinence Syndrome Questions & nswers Webinar #1 (February 9, 2012) Webinar #2 (March 30, 3012) For more information and to download a copy of the NS Clinical Practice Guidelines, please visit
More informationLinking Opioid Treatment in Primary Care. Roxanne Lewin M.D.
Roxanne Lewin M.D. The Facts Fewer than 10 percent of individuals with an alcohol use disorder and only about 20 percent of individuals with an opioid use disorder receive specialty treatment. Many individuals
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Methadone and buprenorphine for the management of opioid dependence
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Appraisal Methadone and buprenorphine for the management of opioid dependence Comments received from Consultees and Commentators on the draft scope
More informationCAM2038 A new liquid-lipid crystal depot buprenorphine: A dose-ranging suite of weekly and monthly subcutaneous depot injections
CAM2038 A new liquid-lipid crystal depot buprenorphine: A dose-ranging suite of weekly and monthly subcutaneous depot injections Dr. Fredrik Tiberg Assoc. Prof. President & CEO, Head R&D, Camurus Lund,
More informationGOALS AND OBJECTIVES
SUBOXONE AND VIVITROL: ARE THERE DISPARITIES SURFACING IN MEDICATION ASSISTED TREATMENTS? P R E S E N T E D B Y D R. K I AM E M AH A N I A H & D R. M Y E C H I A M I N T E R - J O R D AN GOALS AND OBJECTIVES
More informationSubstance use and misuse
An open learning programme for pharmacists and pharmacy technicians Substance use and misuse Educational solutions for the NHS pharmacy workforce DLP 160 Contents iii About CPPE open learning programmes
More informationPublic Policy Statement on the Regulation of Office-Based Opioid Treatment
Public Policy Statement on the Regulation of Office-Based Opioid Treatment Background Office-based opioid treatment (OBOT) commonly refers to outpatient treatment services provided outside of licensed
More informationOpioid Agonists. Natural derivatives of opium poppy - Opium - Morphine - Codeine
Natural derivatives of opium poppy - Opium - Morphine - Codeine Opioid Agonists Semi synthetics: Derived from chemicals in opium -Diacetylmorphine Heroin - Hydromorphone Synthetics - Oxycodone Propoxyphene
More informationEarl Hightower's Remarks 2014 National Rx Drug Abuse Summit Medication Assisted Treatment for Opiate Addiction
Earl Hightower's Remarks 2014 National Rx Drug Abuse Summit Medication Assisted Treatment for Opiate Addiction Thank you, Chairman Rogers, for holding this important Summit and helping to bring attention
More informationOpioids Research to Practice
Opioids Research to Practice May 2013 Daniel P. Alford, MD, MPH, FACP, FASAM Associate Professor of Medicine Assistant Dean, Continuing Medical Education Case 32 yo female brought in after heroin overdose
More informationSHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION
SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION Naltrexone is used as part of a comprehensive programme of treatment against alcoholism to reduce the
More informationCOGNITION IN DRUG AND ALCOHOL SERVICES
COGNITION IN DRUG AND ALCOHOL SERVICES Authors: Perry N 1, Monds L 2,3, Ridley N 2, Malcolm A 2, Finsterer K 2, Bruno R 4, Cheung M 4, Chau V 4, Marceau EM 5, Lunn J 6, Berry J 7, Kelly PJ 5, Solowij N
More informationNow available. A maintenance dose of SUBOXONE mg once daily is clinically effective for most patients*1. Once-daily dosing in a single tablet
Now available SUBOXONE Once-daily dosing1 12 mg and 16 mg tablets A maintenance dose of SUBOXONE 12-16 mg once daily is clinically effective for most patients*1 Effective maintenance dosing with SUBOXONE
More informationTITLE: Crushed Buprenorphine or Buprenorphine-Naloxone for Opioid Dependency: A Review of the Clinical Effectiveness and Guidelines
TITLE: Crushed Buprenorphine or Buprenorphine-Naloxone for Opioid Dependency: A Review of the Clinical Effectiveness and Guidelines DATE: 18 July 2016 CONTEXT AND POLICY ISSUES Opioid dependence is a chronic
More informationReferral to the Women s Alcohol and Drug Service (WADS) Procedure
1. Purpose The following document describes criteria for the referral to Women s Alcohol and Drug Service (WADS) and how a referral is taken and processed. This includes the referral for clinical care
More informationThe Prescription Review Program and College Expectations. Dr. Rashmi Chadha MBChB MScCH CCFP MRCGP Dip. ABAM
The Prescription Review Program and College Expectations Dr. Rashmi Chadha MBChB MScCH CCFP MRCGP Dip. ABAM April 28, 2017 Disclosure Relationship with commercial interests: None Professional roles: Addictions
More informationTreatment of Pain in an Emergent Setting
Updated: October 22, 2018 Prescribing Guidelines for Pennsylvania Treatment of Pain in an Emergent Setting Opioids, including heroin and fentanyl, contribute to thousands of overdose deaths in Pennsylvania
More informationModule Two: Pharmacotherapies for Opioid Substitution Treatment
Module Two: Pharmacotherapies for Opioid Substitution Treatment Neurobiology of Addiction Pharmacology of Opioids Methadone Buprenorphine Pharmacokinetics of Methadone & Buprenorphine Opioid effects Intoxication
More informationSUBSTANCE ABUSE IN THE ELDERLY. The Invisible Epidemic
SUBSTANCE ABUSE IN THE ELDERLY The Invisible Epidemic IS IT POSSIBLE TO TEACH AN OLD DOG NEW TRICKS? GUIDELINES All forms of addiction know no age limit. Don t blame all problems on aging. Few realize
More informationOpioid Review and MAT Clinic CDC Guidelines
1 Opioid Review and MAT Clinic CDC Guidelines January 10, 2018 Housekeeping Use chat feature to inform everyone who s at your clinic Click chat on Zoom option bar Chat Everyone the names of those who are
More informationSubstitution Therapy for Opioid Use Disorder The Role of Suboxone
Substitution Therapy for Opioid Use Disorder The Role of Suboxone Methadone/Buprenorphine 101 Workshop, December 10, 2016 Leslie Lappalainen, MD, CCFP, dip ABAM Prepared by Mandy Manak, MD, ABAM, CCSAM
More informationPublications for Paul Haber
Publications for Paul Haber 2018 Nguyen, V., Haber, P., Seth, D. (2018). Applications and Challenges for the use of Phosphatidylethanol Testing in Liver Disease Patients (MINI REVIEW). Alcoholism: Clinical
More informationEvidence-based interventions for managing illicit drug dependence
Evidence-based interventions for managing illicit drug dependence Medical professionals have a key role to play in managing the harms (see Box 1) associated with illicit drug dependence. This can be in
More information9/13/2017. Buprenorphine Treatment (Suboxone) Disclosures. We ve Got a Big Opioid Problem. Selahattin Kurter, MD Spectrum Healthcare
Buprenorphine Treatment (Suboxone) Selahattin Kurter, MD Spectrum Healthcare Board Certified in Psychiatry and Addiction Medicine Disclosures No financial reimbursement for this lecture Consultant for
More informationOPIOIDS AND NON-CANCER PAIN
Ch05.qxd 1/6/04 4:33 PM Page 77 CHAPTER 5 OPIOIDS AND NON-CANCER PAIN Background 78 Side-effects of opioids 78 Tolerance, physical dependence and addiction 79 Opioid-induced pain 79 Practical issues 80
More informationMethadone Maintenance
Methadone Maintenance A Practical Guide to Pharmacotherapy Methadone/Buprenorphine 101 Workshop, April 1, 2017 Ron Joe, MD, DABAM Objectives I. Pharmacology Of Methadone II. Practical Application of Pharmacology
More informationOpioid Dependence and Buprenorphine Management
Opioid Dependence and Buprenorphine Management Kevin Kapila, MD Fenway Health Medical Director of Behavioral Health Instructor in Medicine Harvard Medical School Learning Objectives Understand the rationale
More informationPALLIATIVE CARE PRESCRIBING FOR PATIENTS WHO ARE SUBSTANCE MISUSERS
PALLIATIVE CARE PRESCRIBING FOR PATIENTS WHO ARE SUBSTANCE MISUSERS Background information Substance misusers who develop palliative care needs are likely to have psychological, social and existential
More information(Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines)
Buprenorphine Initiation and Maintenance in Pregnancy (Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines) Assessment The diagnosis of OUD should be confirmed by DSM-5
More informationImplementing Buprenorphine Treatment in Opioid Treatment Programs Webinar 2, October 3, 2018
Implementing Buprenorphine Treatment in Opioid Treatment Programs Webinar 2, October 3, 2018 Judith Martin, MD, Medical Director of Substance Use Services, San Francisco Department of Public Health Webinar
More informationOpioids. October 29, Addiction Medicine Review Course CSAM, Newport Beach, CA
Opioids October 29, 2010 Addiction Medicine Review Course CSAM, Newport Beach, CA Daniel P. Alford, MD, MPH, FACP, FASAM Associate Professor of Medicine Boston University School of Medicine Boston Medical
More informationRECOMMENDATIONS FOR HEALTH CARE PROVIDERS
Ending Addiction Changes Everything RECOMMENDATIONS FOR HEALTH CARE PROVIDERS CRITICAL ADDICTION PREVENTION, TREATMENT AND MANAGEMENT SERVICES TO INCLUDE IN ROUTINE HEALTH CARE PRACTICE JULY 2013 In the
More informationDr. Meldon Kahan. Women s College Hospital. with PIA LAW
with PIA LAW and Toronto ABI Network Dr. Meldon Kahan Women s College Hospital Dr. Meldon Kahan is an Associate Professor in the Department of Family Medicine at University of Toronto, and Medical Director
More informationTake home naloxone in Australia: Past, present and future
National Drug Research Institute Preventing Harmful Drug Use in Australia Take home naloxone in Australia: Past, present and future Simon Lenton NDRI Paul Dietze Burnet ndri.curtin.edu.au Reminder: heroin-related
More informationDrug Misuse and Dependence Guidelines on Clinical Management
Department of Health Scottish Office Department of Health Welsh Office Department of Health and Social Services, Northern Ireland Drug Misuse and Dependence Guidelines on Clinical Management An Executive
More informationAddiction to Opioids. Marvin D. Seppala, MD Chief Medical Officer
Addiction to Opioids Marvin D. Seppala, MD Chief Medical Officer Mayo Clinic Opioid Conference: Evidence, Clinical Considerations and Best Practice Friday, September 30, 2016 26 y.o. female from South
More informationManaging drug misuse in pregnancy and beyond
Managing drug misuse in pregnancy and beyond Dr Emily Finch Clinical Director Addictions CAG, South London and Maudsley Foundation NHS Trust Rachel Evans, Adfam 1 / Aims of the session Update on management
More information